{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:20:10Z","timestamp":1793056810906,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003072","name":"LOEWE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ctro.2022.04.003","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T19:40:42Z","timestamp":1649274042000},"page":"99-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["ACO\/ARO\/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group"],"prefix":"10.1016","volume":"34","author":[{"given":"Maximilian","family":"Fleischmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9042-9729","authenticated-orcid":false,"given":"Markus","family":"Diefenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele M.","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Dieter","family":"Hofheinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian R.","family":"Greten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ctro.2022.04.003_b0005","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","article-title":"Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years","volume":"30","author":"Sauer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2022.04.003_b0010","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1470-2045(12)70116-X","article-title":"Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial","volume":"13","author":"Hofheinz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ctro.2022.04.003_b0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.bpg.2016.06.004","article-title":"Rectal cancer: neoadjuvant chemoradiotherapy","volume":"30","author":"R\u00f6del","year":"2016","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.003_b0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-Course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision (TME) versus Preoperative Chemoradiotherapy, TME, and optional adjuvant chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2022.04.003_b0025","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.003_b0030","doi-asserted-by":"crossref","first-page":"e215445","DOI":"10.1001\/jamaoncol.2021.5445","volume":"8","author":"Fokas","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.ctro.2022.04.003_b0035","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/S1470-2045(20)30024-3","article-title":"Outcome measures in multimodal rectal cancer trials","volume":"21","author":"Fokas","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctro.2022.04.003_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx095","article-title":"Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer","volume":"109","author":"Fokas","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ctro.2022.04.003_b0045","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.003_b0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.003_b0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ccell.2022.01.004","article-title":"Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer","volume":"40","author":"Nicolas","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctro.2022.04.003_b0060","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1200\/EDBK_319783","article-title":"Moving beyond 3+3: the future of clinical trial design","volume":"41","author":"Kurzrock","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"10.1016\/j.ctro.2022.04.003_b0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/cncr.30600","article-title":"Total Neoadjuvant therapy for rectal cancer: an emerging option","volume":"123","author":"Ludmir","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2022.04.003_b0070","doi-asserted-by":"crossref","unstructured":"Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH, Jr, Campos FG, Kiss DR, Gama-Rodrigues J. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240 (4): 711\u2013717; discussion 717-8. https:\/\/doi.org\/10.1097\/01.sla.0000141194.27992.32.","DOI":"10.1097\/01.sla.0000141194.27992.32"},{"issue":"35","key":"10.1016\/j.ctro.2022.04.003_b0075","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1200\/JCO.2011.37.7176","article-title":"Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer","volume":"29","author":"Maas","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.003_b0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe Project): a propensity-score matched cohort analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ctro.2022.04.003_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(21)00304-1","article-title":"Intensifying neoadjuvant treatment in locally advanced rectal cancer","volume":"22","author":"Patel","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.003_b0090","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/codi.13207","article-title":"Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review","volume":"18","author":"Ryan","year":"2016","journal-title":"Colorectal Dis"},{"issue":"10","key":"10.1016\/j.ctro.2022.04.003_b0095","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41591-019-0584-2","article-title":"A rectal cancer organoid platform to study individual responses to chemoradiation","volume":"25","author":"Ganesh","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.003_b0100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"7","key":"10.1016\/j.ctro.2022.04.003_b0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nrc3958","article-title":"The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence","volume":"15","author":"Barker","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"101417","key":"10.1016\/j.ctro.2022.04.003_b0110","article-title":"Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.003_b0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/imr.12978","article-title":"Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer","volume":"302","author":"Mhaidly","year":"2021","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.ctro.2022.04.003_b0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.ctro.2022.04.003_b0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40487-018-0089-z","article-title":"The role of interleukin-1 in the pathogenesis of cancer and its potential as a therapeutic target in clinical practice","volume":"6","author":"Litmanovich","year":"2018","journal-title":"Oncol Ther"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.003_b0130","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/cancers13030477","article-title":"Therapeutic strategies for targeting IL-1 in cancer","volume":"13","author":"Gottschlich","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ctro.2022.04.003_b0135","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ctro.2022.04.003_b0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ctro.2022.04.003_b0145","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ctro.2022.04.003_b0150","first-page":"531","article-title":"Safety profile of Anakinra in the management of rheumatologic, metabolic and autoinflammatory disorders","volume":"34","author":"Lopalco","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.ctro.2022.04.003_b0155","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/14740338.2018.1486819","article-title":"Anakinra for the treatment of rheumatoid arthritis: a safety evaluation","volume":"17","author":"Ram\u00edrez","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.ctro.2022.04.003_b0160","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1474319","article-title":"Fluorouracil and bevacizumab plus Anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study","volume":"7","author":"Isambert","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctro.2022.04.003_b0165","doi-asserted-by":"crossref","unstructured":"Whiteley A, Becerra C, McCollum D, Paulson AS, Goel, A. A Pilot, Non-randomized evaluation of the safety of Anakinra plus FOLFIRINOX in metastatic pancreatic ductal adenocarcinoma patients. J Clin Oncol 2016; 34(15_suppl): e15750. https:\/\/doi.org\/10.1200\/jco.2016.34.15_suppl.e15750.","DOI":"10.1200\/JCO.2016.34.15_suppl.e15750"},{"issue":"15_suppl","key":"10.1016\/j.ctro.2022.04.003_b0170","doi-asserted-by":"crossref","first-page":"e14565","DOI":"10.1200\/JCO.2016.34.15_suppl.e14565","article-title":"Safety and immunologic activity of Anakinra in HER2-Negative Metastatic Breast Cancer (MBC)","volume":"34","author":"O\u2019Shaughnessy","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctro.2022.04.003_b0175","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.2018.36.4_suppl.449","article-title":"Gemcitabine Nab-Paclitaxel, Cisplatin, and Anakinra (AGAP) Treatment in Patients with Localized Pancreatic Ductal Adenocarcinoma (PDAC)","volume":"36","author":"Becerra","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082200026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082200026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:09:14Z","timestamp":1762502954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082200026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":35,"alternative-id":["S240563082200026X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2022.04.003","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACO\/ARO\/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2022.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}]}}